ATE198910T1 - Retrovirale vektoren - Google Patents

Retrovirale vektoren

Info

Publication number
ATE198910T1
ATE198910T1 AT97909436T AT97909436T ATE198910T1 AT E198910 T1 ATE198910 T1 AT E198910T1 AT 97909436 T AT97909436 T AT 97909436T AT 97909436 T AT97909436 T AT 97909436T AT E198910 T1 ATE198910 T1 AT E198910T1
Authority
AT
Austria
Prior art keywords
vector particle
vector
retroviral vectors
lentivirus
infecting
Prior art date
Application number
AT97909436T
Other languages
English (en)
Inventor
Alan John Kingsman
Susan Mary Kingsman
Narry Kim
Kyriacos Mitrophanous
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621680.9A external-priority patent/GB9621680D0/en
Priority claimed from GBGB9624457.9A external-priority patent/GB9624457D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE198910T1 publication Critical patent/ATE198910T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
AT97909436T 1996-10-17 1997-10-17 Retrovirale vektoren ATE198910T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621680.9A GB9621680D0 (en) 1996-10-17 1996-10-17 Lentiviral vectors
GBGB9624457.9A GB9624457D0 (en) 1996-11-25 1996-11-25 Retroviral vectors
PCT/GB1997/002857 WO1998017815A1 (en) 1996-10-17 1997-10-17 Retroviral vectors

Publications (1)

Publication Number Publication Date
ATE198910T1 true ATE198910T1 (de) 2001-02-15

Family

ID=26310246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909436T ATE198910T1 (de) 1996-10-17 1997-10-17 Retrovirale vektoren

Country Status (23)

Country Link
US (2) US6312682B1 (de)
EP (2) EP0904392B1 (de)
JP (2) JP4418536B2 (de)
KR (1) KR20000049251A (de)
CN (1) CN1195863C (de)
AT (1) ATE198910T1 (de)
AU (1) AU725143B2 (de)
BG (1) BG103397A (de)
CA (1) CA2267636A1 (de)
CZ (1) CZ137399A3 (de)
DE (1) DE69703974T2 (de)
DK (1) DK0904392T3 (de)
ES (1) ES2153654T3 (de)
GB (1) GB2325003B (de)
GR (1) GR3035600T3 (de)
HK (2) HK1014993A1 (de)
HU (1) HUP0000421A2 (de)
IL (1) IL129017A0 (de)
NO (1) NO991781L (de)
NZ (1) NZ334860A (de)
PL (1) PL332875A1 (de)
PT (1) PT904392E (de)
WO (1) WO1998017815A1 (de)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU725143B2 (en) * 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
AU752753B2 (en) * 1997-04-09 2002-09-26 Lung-Ji Chang Animal model for evaluation of vaccines
JP4390860B2 (ja) 1997-05-13 2009-12-24 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル レンチウイルスをベースにした遺伝子転移ベクター
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
ATE528405T1 (de) * 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
DK1076715T3 (da) 1998-05-13 2007-11-19 Genetix Pharmaceuticals Inc Lentivirale pakkeceller
WO1999067400A1 (en) 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
ATE368122T1 (de) * 1999-04-29 2007-08-15 Cell Genesys Inc Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
EP1282702B1 (de) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
GB0024550D0 (de) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20050267061A1 (en) * 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
ES2582028T3 (es) * 2001-06-29 2016-09-08 Sloan-Kettering Institute For Cancer Research Vector que codifica el gen de la globulina humana y uso del mismo en el tratamiento de hemoglobinopatías
ATE527347T1 (de) * 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
KR20040054699A (ko) * 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물
JP4598398B2 (ja) 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド ウイルスベクター
GB0221778D0 (en) * 2002-09-19 2002-10-30 Molmed Spa Conjugate
CN1759182A (zh) * 2002-11-22 2006-04-12 克雷顿研究院 调节基因的组合物和系统
EP2390352A1 (de) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
WO2005112544A2 (en) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
US7534775B2 (en) * 2004-04-08 2009-05-19 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
JP2007535329A (ja) * 2004-04-29 2007-12-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 細胞接着性を増強する方法および組成物
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP1951751B1 (de) 2005-11-14 2017-11-01 Merial, Inc. Gentherapie bei nierenversagen
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
WO2009039192A2 (en) 2007-09-17 2009-03-26 The Regents Of The University Of Californina Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
CA2705862C (en) 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
WO2009079373A2 (en) * 2007-12-14 2009-06-25 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
ES2762864T3 (es) 2008-06-18 2020-05-26 Oxford Biomedica Ltd Purificación de virus
DK2414386T3 (en) 2009-04-03 2016-02-22 Merial Ltd Birds of vaccines with newcastle disease virus vectors
DK2575894T3 (en) 2010-05-28 2015-05-26 Oxford Biomedica Ltd FEED lentiviral vectors FOR BRAIN
ES2609847T3 (es) 2010-08-31 2017-04-24 Merial, Inc. Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (de) 2011-04-04 2014-02-12 Netherland Cancer Institute Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung mit proteinkinasehemmern
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2834288A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
US10166188B2 (en) 2011-08-12 2019-01-01 Merial, Inc. Method for vacuum-assisted preservation of biologics including vaccines
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
EP2968514A1 (de) 2013-03-12 2016-01-20 Merial, Inc. Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon
AU2014230599B2 (en) * 2013-03-13 2020-02-27 Misako KATSURA Microvesicle, and manufacturing method for same
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
KR20160075676A (ko) 2013-10-24 2016-06-29 오스페달레 산 라파엘 에스.알.엘. 방법
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3313864B1 (de) 2015-06-23 2021-07-28 Boehringer Ingelheim Animal Health USA Inc. Rekombinante prrsv-virusvektoren mit minor-protein und verfahren zur herstellung und verwendung davon
CN116334143A (zh) 2015-11-23 2023-06-27 诺华股份有限公司 优化的慢病毒转移载体及其用途
EP3383920B1 (de) 2015-11-30 2024-01-10 The Regents of the University of California Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3455347A4 (de) 2016-05-10 2019-10-02 United States Government as Represented by The Department of Veterans Affairs Lentivirale abgabe von crispr/cas-konstrukten, die für hiv-1 infektion und -replikation essentielle gene spalten
DK3455239T3 (da) * 2016-05-13 2021-07-05 Flash Therapeutics Partikel til indkapsling af et genomteknisk system
EP3525583A4 (de) 2016-10-12 2020-06-10 Bioverativ USA Inc. Anti-cs1-antikörper und verfahren zur verwendung davon
KR102539159B1 (ko) 2016-11-07 2023-06-02 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
ES2965475T3 (es) 2017-02-12 2024-04-15 Biontech Us Inc Métodos y composiciones basados en HLA y usos de los mismos
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
EP3645040A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur krebsbehandlung
WO2019003159A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
CN110972463A (zh) 2017-06-27 2020-04-07 纽洛可科学有限公司 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
CN111527105A (zh) 2017-10-11 2020-08-11 美国比奥维拉迪维股份有限公司 诱导补体活性的方法
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
EP3746136A1 (de) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Verwendung von lentiviralen vektoren, die faktor viii exprimieren
CN112424223A (zh) 2018-04-24 2021-02-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
US20210228627A1 (en) 2018-05-15 2021-07-29 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
SG11202012978VA (en) 2018-06-25 2021-01-28 Ospedale San Raffaele Srl Gene therapy
EP3841124A4 (de) 2018-06-29 2022-03-23 ApitBio, Inc. Anti-l1cam-antikörper und verwendungen davon
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CA3115902A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
AU2019380517A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
EP3880231A1 (de) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus il-7-protein und einem immunprüfpunktinhibitor
WO2020117992A1 (en) * 2018-12-04 2020-06-11 The Broad Institute, Inc. Improved vector systems for cas protein and sgrna delivery, and uses therefor
US20200199626A1 (en) 2018-12-06 2020-06-25 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840A (zh) 2018-12-21 2021-10-01 百欧恩泰美国公司 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统
EP3937985A1 (de) 2019-03-10 2022-01-19 Sio Gene Therapies Inc. Gentherapiezusammensetzungen und verfahren zur behandlung von morbus parkinson
GB201905244D0 (en) 2019-04-12 2019-05-29 Ospedale San Raffaele Method for analysisng insertion sites
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
CA3152600A1 (en) 2019-09-30 2021-04-08 Andrew KROETSCH Lentiviral vector formulations
CN114667161A (zh) 2019-11-12 2022-06-24 牛津生物医学（英国）有限公司 生产系统
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
EP4093751A1 (de) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimäre polypeptide
EP4093752A2 (de) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimäre polypeptide
KR20220137630A (ko) 2020-02-05 2022-10-12 워싱턴 유니버시티 Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20220154734A (ko) 2020-03-13 2022-11-22 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터
WO2021202604A1 (en) 2020-03-31 2021-10-07 Sana Biotechnology, Inc. Targeted lipid particles and compositions and uses thereof
EP4143326A1 (de) 2020-04-27 2023-03-08 University of Iowa Research Foundation Zusammensetzungen und verfahren zur behandlung von zystischer fibrose
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
CN116033927A (zh) 2020-06-24 2023-04-28 比奥维拉迪维治疗股份有限公司 从经修饰以表达因子viii的慢病毒载体的制剂中去除游离因子viii的方法
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
EP4204447A1 (de) 2020-08-28 2023-07-05 Sana Biotechnology, Inc. Modifizierte antivirale bindemittel
IL302031A (en) 2020-10-12 2023-06-01 Ospedale San Raffaele Srl RAG1 replacement for use in therapy
US20230398216A1 (en) 2020-10-22 2023-12-14 Lyell Immunopharma, Inc. Chimeric activation receptors
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
GB202019108D0 (en) 2020-12-03 2021-01-20 Ospedale San Raffaele Srl Vector
CN117083081A (zh) 2020-12-14 2023-11-17 百欧恩泰美国公司 用于癌症免疫疗法的组织特异性抗原
TW202302841A (zh) 2020-12-31 2023-01-16 美商薩那生物科技公司 用於調變ｃａｒ－ｔ活性之方法與組成物
WO2022150731A1 (en) 2021-01-11 2022-07-14 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
CN117545844A (zh) 2021-02-15 2024-02-09 圣拉斐尔医院有限责任公司 用于癌症治疗的表观遗传沉默
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter
EP4329822A1 (de) 2021-04-26 2024-03-06 CSL Behring L.L.C. Lentivirale vektoren zur behandlung von krankheiten
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CA3219487A1 (en) 2021-05-28 2022-12-01 Richard C. Mulligan Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (de) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-defiziente immunzellen und verwendungen davon
IL310089A (en) 2021-07-14 2024-03-01 Sana Biotechnology Inc Differential expression of Y-linked antigens in hypoimmunogenic cells
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
WO2023062030A1 (en) 2021-10-12 2023-04-20 Ospedale San Raffaele S.R.L. Polynucleotides useful for correcting mutations in the rag1 gene
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
TW202342498A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科融合醣蛋白
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
EP4209511A1 (de) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84-antikörper amd chimäre antigenrezeptoren
WO2023131657A1 (en) 2022-01-05 2023-07-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
GB202204272D0 (en) 2022-03-25 2022-05-11 Ucl Business Ltd Method for engineering innate-like lymphocytes
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
WO2024003578A1 (en) 2022-07-01 2024-01-04 The University Of Bristol Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
WO2024008950A1 (en) 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
EP4303226A1 (de) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgen-kassetten und epigenetische schalldämpfer zur behandlung von störungen
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213894A3 (de) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defektive Viruspartikelimpfstoffe und Verfahren zur Anwendung derselben
EP0536234A4 (en) * 1990-06-20 1993-09-15 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
CA2109579A1 (en) * 1991-05-29 1992-12-10 Julianna Lisziewicz Eukaryotic expression vectors with regulation of rna processing
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Res Found Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
EP0759471A4 (de) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co Rekombinanter vektor bestehend aus dem menschlichen immunschwäche-virus und verfahren zu seiner herstellung
US6326007B1 (en) * 1995-07-20 2001-12-04 The Regents Of The University Of California Attenuated lentivirus vectors expressing interferon
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997014809A2 (en) * 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
AU725143B2 (en) * 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors

Also Published As

Publication number Publication date
CZ137399A3 (cs) 1999-07-14
EP1041152A1 (de) 2000-10-04
AU4712297A (en) 1998-05-15
GB9815778D0 (en) 1998-09-16
ES2153654T3 (es) 2001-03-01
NZ334860A (en) 2001-02-23
CN1195863C (zh) 2005-04-06
PT904392E (pt) 2001-06-29
DE69703974T2 (de) 2001-07-19
EP0904392A1 (de) 1999-03-31
KR20000049251A (ko) 2000-07-25
BG103397A (en) 2000-07-31
DE69703974D1 (de) 2001-03-01
EP0904392B1 (de) 2001-01-24
IL129017A0 (en) 2000-02-17
HUP0000421A2 (hu) 2000-06-28
US6312682B1 (en) 2001-11-06
JP2009291205A (ja) 2009-12-17
PL332875A1 (en) 1999-10-25
NO991781L (no) 1999-06-17
HK1016651A1 (en) 1999-11-05
WO1998017815A1 (en) 1998-04-30
US20020034502A1 (en) 2002-03-21
JP2001502539A (ja) 2001-02-27
GR3035600T3 (en) 2001-06-29
US6669936B2 (en) 2003-12-30
CA2267636A1 (en) 1998-04-30
JP4855504B2 (ja) 2012-01-18
NO991781D0 (no) 1999-04-14
GB2325003B (en) 2000-05-10
AU725143B2 (en) 2000-10-05
DK0904392T3 (da) 2001-04-30
CN1234836A (zh) 1999-11-10
HK1014993A1 (en) 1999-10-08
GB2325003A (en) 1998-11-11
JP4418536B2 (ja) 2010-02-17

Similar Documents

Publication Publication Date Title
DK0904392T3 (da) Retrovirale vektorer
ATE520783T1 (de) Lentivirale vektoren
Boyle et al. Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins.
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
BR8605053A (pt) Processos para a preparacao de um polipeptidio,para a preparacao de um gene sintetico,para a preparacao de um vetor de expressao,para a preparacao de um transformante bacteriano,para a determinacao de anticorpos e de virus,para a preparacao de vacina,vacinas,anticorpos,polipeptidos,gene,vetor,transformante,kit de teste
DE69734829D1 (de) Infektiöse pseudovirale papillomavirus partikel
DE60044754D1 (de) Trans-lentivirales Vektor System
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
AU630861B2 (en) Recombinant hiv-2 polypeptides
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
ATE393819T1 (de) Verwendungen von immortalisierten, homozygoten stat1-defizienten säugerzelllinien
AU5482896A (en) Fusion protein delivery system and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification